Tadashi Hirose
Direttore/Membro del Consiglio presso Prolexys Pharmaceuticals, Inc.
Posizioni attive di Tadashi Hirose
Società | Posizione | Inizio | Fine |
---|---|---|---|
Prolexys Pharmaceuticals, Inc.
Prolexys Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Prolexys Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering small molecule drugs that act at novel therapeutic targets. The Company's therapeutic focus is on cancer and cardiovascular indications. Prolexys scientists have exploited proprietary proteomics-related techniques to rapidly and accurately identify drug candidates that interact with targets of interest. The result of targeted drug discovery work at Prolexys is a pipeline of product candidates with high value in areas of unmet medical need. Lead programs include: a) Solid tumor oncology program with a small molecule clinical candidate with selective anti-tumor activity, b) The colon cancer program with novel small molecule compounds targeting the beta-catenin signaling cascade and c) HSP20 antagonists, identified as protein interaction inhibitors from targets validated in asthma and vasorelaxation. | Direttore/Membro del Consiglio | - | - |
Storia della carriera di Tadashi Hirose
Precedenti posizioni note di Tadashi Hirose
Società | Posizione | Inizio | Fine |
---|---|---|---|
HITACHI, LTD. | Corporate Officer/Principal | 01/04/1975 | - |
Formazione di Tadashi Hirose
Keio University | Graduate Degree |
Statistiche
Distribuzione geografica
Giappone | 3 |
Stati Uniti | 2 |
Posizioni
Director/Board Member | 1 |
Graduate Degree | 1 |
Undergraduate Degree | 1 |
Settori
Health Technology | 2 |
Consumer Services | 2 |
Producer Manufacturing | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Società quotate in Borsa | 1 |
---|---|
HITACHI, LTD. | Producer Manufacturing |
Aziende private | 1 |
---|---|
Prolexys Pharmaceuticals, Inc.
Prolexys Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Prolexys Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering small molecule drugs that act at novel therapeutic targets. The Company's therapeutic focus is on cancer and cardiovascular indications. Prolexys scientists have exploited proprietary proteomics-related techniques to rapidly and accurately identify drug candidates that interact with targets of interest. The result of targeted drug discovery work at Prolexys is a pipeline of product candidates with high value in areas of unmet medical need. Lead programs include: a) Solid tumor oncology program with a small molecule clinical candidate with selective anti-tumor activity, b) The colon cancer program with novel small molecule compounds targeting the beta-catenin signaling cascade and c) HSP20 antagonists, identified as protein interaction inhibitors from targets validated in asthma and vasorelaxation. | Health Technology |
- Borsa valori
- Insiders
- Tadashi Hirose
- Esperienza